

Manuscript Number:

Title: Allogeneic Amniotic Membrane-derived 3-Dimensional Culture of Mesenchymal Stem Cells Promotes Rapid Burn Wound Closure in A Non-Human Primate Burn Wound Injury Model

Article Type: Research Paper

Keywords: Amniotic membrane MSCs; 3-dimensions (3D) micro-carrier; Non-human primate third-degree burn injury model; HGF; VEGF; Collagen

Corresponding Author: Dr. Ahmad Faried, MD., PhD

Corresponding Author's Institution: Universitas Padjadjaran

First Author: Rachmawati Noverina

Order of Authors: Rachmawati Noverina; Ahmad Faried, MD., PhD; Wireni Ayuningtyas; Dedy Kurniawan; Hendrikus Bolly; Indra Bachtiar; Firman F Wirakusumah

Abstract: Background. Amniotic membrane is a laboratory medical waste that potentially serves as a good source of mesenchymal stem cell (AM-MSCs). This study is aimed to investigate the feasibility and safety of allogeneic three-dimensional (3D) micro-carrier cultures of AM-MSCs transplantation that promotes rapid closure of the third-degree burns wound using non-human primate (NHP), *Macaca fascicularis*, burn wound injury model. Methods. AM-MSCs was isolated by standard protocol in two-dimensional (2D) cultures following the increasing process of cells in 3D micro-carrier cultures. These were analyzed for its morphology, ability to proliferate, surface markers and multilineage differentiation potential. The 3D AM-MSCs were then injected under the burns wound lesion of the NHP burn wound injury model. Then, we observed the growth factors, the speed of healing process and the scars formation of 3D AM-MSCs, compared to the gold standard treatment of silver sulfadiazine (Burnazine) ointment. Samples treated with the physiological sodium chloride (NaCl 0,9%) served as a negative control. Results. The surface antigen phenotype, morphology and differentiation characteristics of 3D AM-MSCs exhibited properties of MSCs. The speed of wound closure was

significantly accelerated when 3D AM-MSCs were applied in NHP burn wound injury model compared to the group with topical application of Burnazine ointment. HGF and VEGF levels were increased, and there were no scars formation on the lesions treated with 3D AM-MSCs. The healing speed were quickly restored, and we found new hair growth in the lesion area found in 3D AM-MSCs-group. Conclusion. 3D AM-MSCs transplantation effectively promotes rapid wound closure in NHP burn wound model. The large amount of cells requirement are solved by 3D cultures that will facilitate the development and improve the burn treatment in clinical set-up.

Preprint not peer reviewed

Original Article

Manuscript title:

**Allogeneic Amniotic Membrane-derived 3-Dimensional Culture of Mesenchymal Stem Cells Promotes Rapid Burn Wound Closure in A Non-Human Primate Burn Wound Injury Model**

Running title:

**Allogeneic amniotic membrane-derived mesenchymal stem cells for therapy of burn injury**

Authors:

**Rachmawati Noverina<sup>1,2</sup>, Ahmad Faried<sup>3</sup>, Wireni Ayuningtyas<sup>1,4</sup>, Dedy Kurniawan<sup>1</sup>, Hendrikus Bolly<sup>2,4</sup>, Indra Bachtiar<sup>5</sup>, Firman F. Wirakusumah<sup>6</sup>**

Authors Affiliation:

<sup>1</sup>PT. Bio Farma (Persero), Bandung, Indonesia; <sup>2</sup>Doctoral Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; <sup>3</sup>Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; <sup>4</sup>Magister Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; <sup>5</sup>Stem Cell and Cancer Institute, PT. Kalbe Farma, Jakarta, Indonesia; <sup>6</sup>Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia

\*All correspondence to: **Ahmad Faried, MD., PhD**

Department of Neurosurgery, Faculty of Medicine, Padjadjaran University (UNPAD)–Dr. Hasan Sadikin Hospital (RSHS), Bandung, Indonesia

Authors' email address

**Rachmawati Noverina** : rnoverina@gmail.com  
**Ahmad Faried** : faried.fkup@gmail.com  
**Wireni Ayuningtyas** : wireni.ayuningtyas@gmail.com  
**Dedy Kurniawan** : rudededy@hotmail.com  
**Hendrikus Bolly** : hendrikusbolly@gmail.com  
**Indra Bachtiar** : nantenine@yahoo.com  
**Firman F Wirakusumah**: firman\_fuad@yahoo.com

## Abstract

**Background.** Amniotic membrane is a laboratory medical waste that potentially serves as a good source of mesenchymal stem cell (AM-MSCs). This study is aimed to investigate the feasibility and safety of allogeneic three-dimensional (3D) micro-carrier cultures of AM-MSCs transplantation that promotes rapid closure of the third-degree burns wound using non-human primate (NHP), *Macaca fascicularis*, burn wound injury model.

**Methods.** AM-MSCs was isolated by standard protocol in two-dimensional (2D) cultures following the increasing process of cells in 3D micro-carrier cultures. These were analyzed for its morphology, ability to proliferate, surface markers and multi-lineage differentiation potential. The 3D AM-MSCs were then injected under the burns wound lesion of the NHP burn wound injury model. Then, we observed the growth factors, the speed of healing process and the scars formation of 3D AM-MSCs, compared to the gold standard treatment of silver sulfadiazine (Burnazine) ointment. Samples treated with the physiological sodium chloride (NaCl 0,9%) served as a negative control.

**Results.** The surface antigen phenotype, morphology and differentiation characteristics of 3D AM-MSCs exhibited properties of MSCs. The speed of wound closure was significantly accelerated when 3D AM-MSCs were applied in NHP burn wound injury model compared to the group with topical application of Burnazine ointment. HGF and VEGF levels were increased, and there were no scars formation on the lesions treated with 3D AM-MSCs. The healing speed were quickly restored, and we found new hair growth in the lesion area found in 3D AM-MSCs-group.

**Conclusion.** 3D AM-MSCs transplantation effectively promotes rapid wound closure in NHP burn wound model. The large amount of cells requirement are solved by 3D cultures that will facilitate the development and improve the burn treatment in clinical set-up.

**Key words:** Amniotic membrane MSCs, 3-dimensions (3D) micro-carrier, Non-human primate third-degree burn injury model, HGF, VEGF, Collagen.

## **Introduction**

Burns are one of the most common and devastating forms of trauma worldwide. Most deaths in burn-injured patients are due to sepsis and its complications.<sup>1</sup> The vast majority of burn wound complications can be prevented by proper early management to prevent pain, discomfort and minimal scar formation.<sup>2,3</sup> Burn wound are classified based on its depth and severity:

1. First-degree (superficial) burns are burns that only affect the epidermis or the outer layer of skin. The burn site is red, painful, dry and with no blisters formation. Mild sunburn is an example. Long-term tissue damage is rare in this grade of burn and usually manifests of an increase or decrease in the skin color; wherein a white plaque and minor pain occur at the site of injury and repair takes place spontaneously. The burn wound resolves within 3 to 4 days without any complication.
2. Second-degree (partial thickness) burns involves all layers of epidermis, the upper part of the dermis (papillary dermis) and may involve the deep dermis (reticular). The burn site appears red (erythematous), with forming of superficial blisters, and might be swollen and painful. The burn wound has a longer healing process of about one month, with minimal cicatrix sequelae.
3. Third-degree (deep partial and full thickness) burns destroys the whole thickness of epidermis, dermis and might also affect the subcutaneous tissue. The burn site may appear white or charred.

4. Fourth degree burns also damage the underlying bones, a deeper muscles layer, tendons and ligament tissue. There is no sensory sensation since the nerve endings are also destroyed.

Of all the burn cases, most patients present with second-degree and third-degree burn injuries.<sup>5</sup> The healing process of burn wounds involves 3 phases: inflammation, proliferation and remodelling.

The mesenchymal stem cells (MSCs) are multipotent adult stem cells which are abundant in human tissue. MSCs are classified in accordance with their tissue of origin, such as amniotic membrane MSCs (AM-MSCs), bone marrow MSCs (BM-MSCs), adipose MSCs and umbilical cord MSCs (UC-MSCs). It has been proven that MSCs can be propagated *in vitro* and retain their multipotency through multiple passages. Moreover, MSCs can differentiate into bone, cartilage, adipose tissue, muscle, neurons, liver cells and cardiocytes, among other cell types.<sup>6,7</sup> Among these MSCs, AM-MSCs are thought to play a key role in wound healing.<sup>8</sup> AM-MSCs thus show tremendous potential to improve burn wound healing in many of rodent and rabbit models.<sup>9,10</sup>

*Macaca fascicularis* or a long-tailed macaque or crab-eating monkey; a laboratory animal, as known as Cynomolgus monkey, *Macaca irus* and *Simia aygula* (Raffles, 1821). *Macaca fascicularis* is a native animal of Southeast Asia, including Indonesia, Malaysia, Thailand, Indochina (see its distribution area in Fig. 1). The habitat of *Macaca fascicularis* includes tropical and mangrove forests. Usually, they inhabit coastal forests, forests along large rivers, near settlements, mixed gardens or plantations, in some places up to an altitude of 1.300 metre above sea level.<sup>11</sup> Study of an international consortium on the composition of the rhesus monkey genome found that the DNA similarity of non-human primate (NHP) species and humans was 98%. Currently, studies using

primate animals are increasing since many beneficial of primate animals themselves.<sup>12</sup>

The conventional method of culturing stem cells is on two-dimensional (2D) surfaces, which is not amenable for scale up to therapeutic quantities in bioreactors. We have developed a facile and robust methods for maintaining undifferentiated cells in novel three-dimensional (3D) suspension cultures on microcarriers achieving 2- to 4-fold higher cell densities than those in 2D AM-MSCs colony cultures for NHP, *Macaca fascicularis*. Micro-carrier cultures achieved even higher cell-concentrations in suspension spinner flasks, thus opening the prospect of propagation in controlled bioreactors.

In this study, we examined the feasibility and safety of 3D AM-MSCs injection to improve healing of burn wound in a NHP model. To the best of our knowledge, there are no reports on the use of AM-MSC that cultured (3D) to treat severely burn wound injuries in NHP, *Macaca fascicularis* burn wound model. Allogeneic AM-MSCs cultured 3D were injected beneath burn wounds in a NHP model and wound closure was evaluated by assessing wound surface closure efficiency, hepatocyte growth factor (HFG), vascular endothelial growth factor (VEGF), collagen and scars formation.

## **Materials and Methods**

This study was approved by the Ethics Committee of the Institutional of Animal Care and Use Ethics Commission (IACUC) of PT Bio Farma (Persero) No. 01/IACUC-BF/III/2017 with a validity period of 2 years, April 14th, 2017–2019.

### ***Harvest and preparation of Macaca fascicularis Amniotic Membrane***

*Macaca fascicularis* placentas (n=3) from healthy donors (female, age 3-4 years old, 3000 ± 100 gram of body weight, spesific pathogen free for TB, SIV, SV40, Polio type 1, 2, 3, Foamy virus and Herpes B virus, were obtained from selected caesarean sections at the

Unit-3 Laboratory of Animal Test PT. Bio Farma (Persero), Bandung. Under stringent sterile conditions, the harvested placentae were placed in PBS medium containing 2% Antibiotic/Antimycotic. The amniotic membranes were then carefully separated from the chorion, which was then discarded, and the amnion was immediately washed three to five times with 0.9% NaCl solution to remove blood and mucus.

***Isolation of MSCs from Amniotic Membrane (AM-MSCs).***

Amnionic membranes (AM) were separately processed after the isolation according to the isolation protocols of Reinisch et al.,<sup>13</sup> Then, the AM was washed with PBS and digested with enzyme collagenase-1 for 1 hour (h) at 37°C, then filtered using cell strainer, then centrifugated and made into pellets which can be cultured on the plate by adding the appropriate medium. The mechanical method is carried out by washed the membrane with PBS and then chopped fine with scissors and cultured on plate by adding appropriate medium. The plated tissues are air-dried for 10 minutes (mins) before adding growth medium and then air-dried to remove as much PBS-KCL as possible so that tissues adhere to the plastic surface. Medium slowly and gently added. Cultures were maintained in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C. Approximately 3-5 days after explantation, fibroblast-like adherent cells migrated from the tissue fragments. After one week of passage 0 (P0) growth with fresh growth medium replacements every 3 days, the sub-confluence (~80%) adherent cells were collected and replated on new dishes at a density of  $2 \times 10^3$  cells/cm<sup>2</sup> (P1).

***Two-dimensional (2D) Culture of AM-MSCs Macaca fascicularis in a flask.***

Defrosted cryopreserved MSC were plated with 2000 cells/cm<sup>2</sup> in  $\alpha$ MEM proliferation medium. The medium was replaced every 3 to 4 days (d). At near confluency (80%) cells were subcultured until passage 3. The passage 3 harvested cells were used for the 3D

micro-carrier cultivation in spinner flasks.

*Macaca fascicularis* placenta must be immediately processed to isolate MSCs after the birth process with a transfer medium containing DPBS + 2% Antibiotic/Antimycotic up to 125 ml. Isolation was carried out aseptically under BSC class II. The processing procedures were done as follows:

1. The amniotic membrane is released using sterile scissors and tweezers.
2. Processed with transfer medium (PBS+KCL+1% Antibiotic/Antimycotic with pH 7.4).
3. Washed membranes with transfer medium 8 times.
4. Isolation of MSCs from the amniotic membrane is done by a mechanical method by cutting or chopping amniotic membrane tissue with sterile scissors and tweezers (should not be done too smoothly since unwanted tissue can also be filtered).
5. Addition of collagenase 0.7  $\mu$ l, collagenase is dissolved in the DPBS.
6. Samples are incubated for  $\pm$  1 h in a 37°C incubator, every 10 mins is vortex at the end of the incubation.
7. Samples are filtered with a  $\pm$  40  $\mu$ m cell strainer (filtration is carried out and accommodated in the growth medium is done slowly so that the membrane network does not participate filtered (sample impurities).
8. Culture is incubated, then on the first day after isolation, the old medium is wtransferred to a new plate. In the old culture plate, a new medium was replaced. On the first day after isolation, there will be visible AM-MSCs that grow in length.
9. Make sure the growth of AM-MSCs is not over-confluent so that the character of AM-MSCs is maintained with no differentiation.
10. Growth medium is replaced every 3 days and we continually observe whether that the growth of AM-MSCs reaches its confluent > 80% ( $\pm$ 5 days). Make sure the growth of

AM-MSCs is not over-confluent so that the character of AM-MSCs is maintained with no differentiation.

11. Subculture is carried out after the growth of MSCs reaches confluent > 80% (P0) and is planted into a new plate with a cell density of 2000 cells/cm<sup>2</sup>. Calculate the number of cells/cm<sup>2</sup> of explants and population doubling time AM-MSCs with the data obtained.

#### ***Subculture Procedure***

1. TrypLE Select is inserted into a 37°C incubator for ± 20 min (depending on volume).
2. Culture is washed with 2x DPBS.
3. Discard DPBS add TrypLE Select as much as 1/3 of the total volume.
4. Culture is incubated for 8 minutes in the incubator.
5. Medium inactivation is added in the form of FBS 20% with a ratio of medium: TrypLE Select = 1 : 1, when using FBS 10%, a ratio of 2 : 1 is used.
6. If there are still cells that have not yet detached, then washing again with DPBS.
7. The sample is re-suspend so that the colony is single.
8. The cell count is calculated using a hemocytometer with the trypan blue: culture ratio = 1 : 1 (10µl)

#### ***Proliferation Assay***

AM-MSCs were plated in 10 cm culture dish with seeding density of  $2 \times 10^3$  cells/cm<sup>2</sup>. The population doubling (PD) between each passage was calculated using the equation  $PD = [\log_{10} (NH) - \log_{10} (NI)] / \log_{10} 2$ .<sup>14</sup> NH is the number of harvested cells and NI is the number of inoculum cells. PD time (PDT) calculated using the time interval between cell seeding and harvest divided by the PD for that passage, start from P0 to P2.

#### ***Freezing Cells***

1. The culture was centrifuged to remove TrypLE Select, DPBS and medium at a speed

of 300 g for 4 mins,

2. Insert the pellets that have been mixed with FBS: DMSO = 9 : 1 in the volume of 1 ml into the cryo-tube. This procedure was done in cold conditions (using ice),
3. Store the cryo-tube into Mr. Frosty for 1 month (maximum), then transfer the cryo-tube into the liquid nitrogen.

### ***Three-dimensional (3D) Micro-carrier cultures of AM-MSCs in agitated conditions***

To passage AM-MSCs from 2D colony cultures to 3D micro-carrier, cells grown on a tissue culture flask 25 cm<sup>2</sup> were harvested by treatment with TrypLE Select, followed by pipetting to form clumps < 100 µm in diameter, typically ranging from 50-60 µm. Alternatively, a pipette was used to create clumps less than 100 µm.

Cytodex 1 microcarriers beads were used for AM-MSCs cultures. Micro-carriers were rehydrated in calcium- and magnesium-free PBS and sterilized by autoclaving at 121°C for 20 minutes. Then, these were micro-carrier washed three times using basal medium plus 1% antibiotic then adapted in the growth medium complete as much as the total volume of culture in the incubator and fermentor for 1 h. AM-MSCs were cultured at 37°C in 5% CO<sub>2</sub> with 50 rpm agitated for 2 h then increased to 70 rpm. Cells were seeded at 4×10<sup>2</sup> cells/ml for 2mg/ml concentration of cytodex 1 micro-carrier. The cultures were continuously run and cell confluence levels are observed every day. Cell counts were taken every day until harvest time and immunophenotyping was performed after harvesting. Harvesting of the cell and conditioned medium was carried out after the cells confluence on the cytodex 1 micro-carrier reached 80-90%. After cells on the surface of the micro-carrier confluent, agitation was stopped so that the cells and micro-carriers settle down and harvest the used growth medium. Then, the cells were washed with a growth medium without FBS and settled again, then the washing medium was removed.

Cells detached from the micro-carrier use TrypLE Select 10x solution which has warmed to the 37°C temperature with a volume ratio of 1:10 at low agitation of 20 rpm for 6-10 mins. After all the cells are released from the micro-carrier, filtering is carried out using a nylon 100 µm sterile filter bag (in-house filter). The cell was washed with growth medium and ready for use/storage.

### ***Micro-carrier flask cultures***

Mechanically dissociated AM-MSCs obtained from static MC were seeded at a density of  $4 \times 10^2$  cells/ml into a presiliconized (Sigmacote, Sigma-Aldrich) 100 ml erlenmeyer disposable flask (Corning) containing 2mg/ml of micro-carriers in 30 ml of growth medium (Lonza). The culture was incubated inside a controlled incubator at 37°C and 5% CO<sub>2</sub> at initial agitation speed of 20 rpm. After a day, the medium was topped up to 30 ml and agitation speed was increased to 70 rpm; 50% of the spent medium was removed every 2-3 days and replaced with fresh medium. Daily samples were taken for cell counts and FACS analysis was performed at harvest time (5 days on average).

### ***Cell counts***

AM-MSCs were sampled daily as a single cell suspension after detachment with TrypLE Select enzyme. Cells were counted at a confluence of 80-90% on cytodex 1 micro-carrier. Briefly, suspension cultured cells on cytodex 1 micro-carrier were detached by TrypLE Select 10x solution, then incubated 5-10 mins at 37°C, completed medium consisting of 80% MEM- $\alpha$ , 20% FFP, 1% Antibiotic/Antimicotic were added to stop and centrifuged at 1600 rpm, 5 min at 24°C. The pellet of cells was resuspended with trypan blue solution diluted 1:1. Cell number was determined with particle counter (Coulter-counter, Beckman Coulter). Cell viability was determined by trypan blue staining with 1:1 ratio (10 µL).

### ***Immunophenotyping***

According to a recent proposal of the International Society for Cellular Therapy (ISCT),<sup>15</sup> MSCs are multipotent nonhematopoietic progenitors that are phenotypically characterized by expression of several positive markers (e.g. CD73, CD90 and CD105) and the lack of expression of CD11b, CD19, CD34, CD45 and HLA-DR surface molecules.<sup>16,17</sup> Briefly, the MSCs (P3) were incubated for 15 mins at 4°C dark condition with the following antibodies Anti Anti CD73-APC, Anti CD90-FITC, Anti CD105-perCP-CY5.5, Anti Linage-Negative-PE and HLA-DR-FITC (BD Biosciences kit). MSCs were acquired using a FACS Calibur (BD) and analyzed with Cell Quest Pro software.

#### ***Osteogenic, Chondrogenic and Adipogenic Differentiation***

The MSCs (P3) were plated in six-well plate at  $5 \times 10^3$  cells/cm<sup>2</sup>. The cells were incubated in MSCs growth medium in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C for 2 h-4 days. Replace media with pre-warmed complete osteogenesis, chondrogenesis and adipogenesis differentiation medium and continue incubation. MSCs will continue to expand as they differentiate under each conditions. The cultures were refed every 3-4 days. After 21 days or longer under differentiation medium, the medium was removed from the plate and rinsed once with PBS. Cell was fixed using 4% formaldehyde solution for 30 mins, then rinsed 2x with distilled water, and 60% isopropanol was added for 2-5 mins. Aspirate off isopropanol and stain with 2% Alizarin red S solution (pH 4.2) for 2-3 mins, 1% Alcian Blue solution for 30 mins, Oil Red O working solution for 5 mins, then rinsed 3x with distilled water and captured in microscope.

#### ***Non-human primate Burn Wound Injury Model***

Male NHP, *Macaca fascicularis*, ages 3-4 years old; 3000 ± 100 gram of body weight, specific pathogen free for TB, SIV, SV40, Polio type 1, 2, 3, Foamy- and Herpes B-virus, were kept in cages with free access to food and water. Three placental amniotic

membranes from 3 female *Macaca fascicularis* were used for therapy in burn injury model. The full thickness burn sites (n=6) were made on each NHP. Burn wound induction was performed following a Mason-Walker burn model as guideline, with several modifications.<sup>18</sup> On burn induction day (day 0), *Macaca fascicularis* were generally anesthetized using atropine sulfas premedication 0.02-0.05 mg/kg, ketamine 5-10 mg/kg and xylazine 0.1-0.5 mg/kg body weight; before burn wound induction. A digital electrical appliance with a circular stainless steel plate was heated to 120°C, then applied for 20 seconds on a clean-shaved back skin area of the *Macaca fascicularis* to produce a grade 3 burn area of 4 cm diameter. Burns were made in 4 NHP, with 6 sites in total. After 24 h since the burns were made, the treatment was carried out in 4 groups: (i) physiological NaCl 0,9%, (ii) Silver Sulfadiazine (Burnazine), (iii) MSCs-1 dose of  $5 \times 10^5$  cells and (iv) MSCs-2 dose of  $2 \times 10^6$  cells. The observation of burn wound was carried out on days 0, 1, 7, 14, 21 and 28. On the 28<sup>th</sup> day, the study was terminated and humane killing was carried out by using excessive doses of ketamine and perfusion through the heart using NaCl 0,9% and 40% formaldehyde according to the procedure. After the NHP is confirmed dead, the cadaver was then incinerated.

#### ***Assessment of Wound Healing.***

Wound area and diameter were measured every 7 days, started from day 1 until day 28 post-burn wound induction. Wound size was measured by imprinting the wound area on a transparent paper, then the diameter of wound is measured using a caliper.

Then, percentage of wound closure (%) was calculated by formula below:

$$\frac{(\text{Wound Initial Area} - \text{Wound End Area})}{\text{Wound Initial Area}} \times 100\%$$

Initial wound closure (in day 0) was defined as 0% wound closure. The percentage of wound closure is considered as observation data in this study for the next analysis.

### ***ELISA for measure check HGF, VEGF and Collagen levels after treatment***

*Macaca fascicularis*'s burn wound injury model serum sample was checked for its HGF, VEGF and Collagen levels. Growth factors assay measured using ELISA kit at room temperature according to the manufacturer's instructions (*Novex Lifesciences*). Serum was measured in day 1, 7, 14, 21 and 28 according to a standard curve constructed for each assay. The colorimetric absorbance for HGF-concentrations (pg/ml), VEGF- (pg/ml) and Collagen- ( $\mu\text{g/ml}$ ) were analyzed at a wavelength of 450 nm using a microplate reader.

### ***Statistical Analysis***

Six replicates for each experiment were performed. The percentage of wound area and the number of growth factors for each group are presented as mean  $\pm$  standard deviation and were analyzed by analysis of variance followed by Bonferroni's test. Correlation test was done by Pearson correlation test. The observation data were analyzed in order to assess the normality of the data distribution by using Shapiro-Wilk. ANOVA test was used for data that are normally distributed and followed by multiple comparisons post-hoc *Turkey* test, whereas Kruskal Wallis test was used for abnormal distribution data. All the statistical analyses were performed with SPSS software version 25.0 for Windows, with a p-values of  $<0.001$  and  $<0.05$  considered as statistically significant.

## **Result**

### ***Isolation of MSCs from Amniotic Membrane (AM-MSCs)***

The average number of processed 2D AM-MSCs isolated was  $9,6 \times 10^5$ - $1,2 \times 10^6$  cells (n=3) in  $75 \text{ cm}^2$  tissue culture flask (TCF) with mean viability 97,3%; 2D AM-MSCs expanded easily in vitro and exhibited a fibroblast-like morphology (Fig. 2). In flow cytometry,

characteristic expressions of surface markers were confirmed. 2D AM-MSCs expressed CD73, CD90, CD105 and lacking of negative markers; osteogenic, chondrogenic and adipogenic differentiation was also confirmed by conventional method (data not shown).

#### ***Population Doubling Time (PDT) 2-dimensional (2D) vs. 3-dimensional (3D)***

The PDT for each 2D AM-MSCs vs. 3D AM-MSCs isolated cells were shown in Table 1. Statistical analysis was performed to observed the significant different of 2D PDT vs 3D, using independent t-test followed by one tailed of analysis of variance (ANOVA).

#### ***Growth of 3-dimensional (3D) culture of MSC***

In the process of cell culture, the risk of contamination is closely related to the stages in handling culture, such as opening and closing bottles or flasks on a 2D monolayer culture repeatedly. By using micro-carrier in the bioreactor the risk of contamination can be avoided because culture takes place in a closed system and automatically. The sampling process can be carried out without risk of contamination.<sup>19</sup> Cell in 3D micro-carrier is a simulation of cell growth conditions in vivo because cells can grow freely, and were not constrained in the form of plating following the shape of the base as on the surface of a bottle or flask. Therefore, the cells can be rounded (spheroid) or elliptical (ellipsoid), and were able to join (aggregate), communicate and release proper secretions in vivo conditions.<sup>20</sup> In this study it was found that the morphological characteristics can be seen in Fig. 3, it appears that the growing cell adheres to the surface of the cytodex 1 micro-carrier and reached a 90-95% confluence on day 5, spindle-shaped cells like rounded fibroblasts of smaller size than 2D culture in the flask. In this study, it was found that the MSCs size averaged 14  $\mu\text{m}$ .

Three-dimensional MSC culture using cytodex 1 micro-carrier suspension showed that the MSCs growth rate measured as the MSCs proliferation rate with the population

doubling time (PDT) was obtained 1.2 days (29 hours) on average. It can be said that in the 3D environment, the cells grew better because it resembles the actual conditions of cell life in the body (mimicking in vivo conditions), therefore there will be better results in many ways including potential differentiation, morphology, proliferation, cell function general for example against drug response, expression (genes, proteins), stimulating responses and also viability.<sup>21</sup> In other words, cell excellence is seen from its function. Cells that are not natural in an unnatural environment cannot get natural functions.<sup>22</sup> From the results of this study (Fig. 3) it was found that MSCs from *Macaca fascicularis* amniotic membrane included CD clusters that were in accordance with MSCs in humans, namely positive CD clusters (Fig. 4A) for CD73 (98.97%), CD90 (98.80%), CD105 (78.40%) and negative CD clusters (Fig. 4b) for negative cocktail (CD34/CD45/CD11b/CD19/HLA-DR) (0.48%) and HLA-DR (0.37%). In Fig. 5, we can see that the MSC from the amnion membrane of *Macaca fascicularis* which is cultured in 3D using a cytodex 1 micro-carrier suspension in the bioreactor can differentiate into osteocytes by red alizarine staining, chondrocytes with alcian blue and adipocyte with red oil staining.

#### ***Macaca fascicularis* Burn Wound Injury Model**

The development of the percentage of wound closure in our NHP model among negative control (NaCl 0,9%) group, gold standard (Burnazine) group, 3D AM-MSCs  $5 \times 10^5$  and 3D AM-MSCs  $2 \times 10^6$  cells groups. The development of the percentage of wound closure among those four groups on day 7 to 28 was shown in the Fig. 6. There was a significant different of 3D AM-MSCs  $5 \times 10^5$  and  $2 \times 10^6$  cells groups to accelerate wound closure and the hair began to grow on the 14<sup>th</sup> day vs. Burnazine as the gold standard ( $p=0,001$ ). There no significant different between 3D AM-MSCs  $5 \times 10^5$  group vs. 3D AM-MSCs

$2 \times 10^6$  group ( $p=0,887$ ). Furthermore, the representative of the wound closure progress, with or without keloid formation, of four groups was presented in the Fig. 7.

#### ***HGF, VEGF and Collagen Measurement Results using ELISA***

HGF, VEGF and Collagen level was measured using ELISA kit using blood sample taken from treated NHP femoral vein. There are significant differences between 3D AM-MSCs  $5 \times 10^5$  group and  $2 \times 10^6$  group compared to the negative control (NaCl 0,9%) along with gold standard Burnazine in terms of HGF level both on daily basis from day 7 to 28 ( $p=0.000$ ) and on the mean value of HGF ( $p=0.000$ ), Fig. 8A and B respectively. HGF in NaCl 0,9% was too low and not detected. There were significant differences between 3D AM-MSCs  $5 \times 10^5$  group and  $2 \times 10^6$  group compared to negative control (NaCl 0,9%) and gold standard Burnazine in VEGF level both on day 7 to 28 ( $p=0.000$ ) and on the mean value of VEGF ( $p=0.000$ ), Fig. 9 and 8B respectively. VEGF level was decreasing in time dependent manner also VEGF in NaCl 0,9% was too low and not detected. There are significant difference between 3D AM-MSCs  $5 \times 10^5$  and  $2 \times 10^6$  group very low compared to negative control (NaCl 0,9%) and gold standard Burnazine in collagen level both on day 1 to 28 ( $p=0.000$ ) and on the mean value of collagen ( $p=0.000$ ), Fig. 10A and B respectively.

Effect of HGF and VEGF serum levels, on healing burn wound is greater than the collagen. Wound healing of burns treated with 3D AM-MSCs did not cause scarring since the collagen concentration was very low compared to the effects obtained from Burnazine ( $p=0.786$ ), while for MSCs ( $p=0.001$  and  $0.000$ ). It appeared that the wound healing effect of burns are strongly influenced by levels of HGF and VEGF concentrations ( $p=0.001$ ) compared to the effect of collagen concentration ( $p > 0.001$ ).

## Discussion

In the past 30 years, there has been a clear evolution of the conceptual strategy in the field of burns treatment. The each one of the three Rs, "Replace, Reconstruction, Regenerate" has clinical applications in transplantation, tissue engineering and now stem cell therapy.<sup>23,24</sup> MSC is a cell that can renew itself and can differentiate into several other types of cells. MSCs has been isolated from various sources such as placenta, bone marrow, adipose tissue, peripheral blood and other adult tissues. The interesting aspects about MSC lies in its ability to cure degenerative diseases, and MSC is currently in the phase of clinical studies. Three remarkable things about stem cells are their role in the field of cell therapy, regenerative therapy and the discovery of new drugs in animal and human models.<sup>25</sup>

Animal models have greatly improved our understanding of the cause and progression of many human diseases and have proven to be a useful tool for discovering therapeutic drugs. Previous reports found that DNA sequence similarities between NHPs and humans can reach up to 98.77%<sup>26</sup> and the concordances rates of gene transcription levels of spleen, peripheral blood monocyte cells (PBMCs) and liver between NHPs and humans can reach as high 91.41%, 84.36% and 74.29%, respectively.<sup>27</sup> The data garnered from such NHP experiments is invaluable as a starting point, because it ensures greater efficiency and surety of future clinical application, making NHPs the "gold standard" for preclinical studies.<sup>28</sup> For burn wound studies, in vitro models are limited in their ability to capture all aspects of burn pathophysiology and the complex clinical features of human burn wound injury. NHPs are phylogenetically close to humans, with many similarities in terms of physiology, anatomy, immunology, as well as neurology, all of which make them excellent experimental models for biomedical research such as burn wound injury.

The current 2D tissue culture platform can be used when low doses are needed and it becomes impractical when doses above  $50 \times 10^6$  are needed; especially considering the high risk of cells contamination along its productions for in-and-out incubator repeatedly. We were interested in the usage of the micro-carrier platform to generate stem cells in a scalable 3D manner. MSCs originally grow as monolayer, as we developed method to culturing MSCs to a micro-carrier based expansion platform. To this date, the usage of micro-carrier has been limited mainly to vaccine production. However, in terms of bioprocessing unit that demanding a large scale of cells productions and the low risk of contamination, 3D micro-carrier platform were able to provide an alternative solution for its application, since the system are closed and automatic. In this present study, we also compared 2D AM-MSCs with 3D AM-MSCs, and our results indicated that there were no differences in terms of differentiation *in vitro*, in specific cell marker expression but only in cell population doubling time, suggesting that 3D AM-MSCs grow much faster in term of PDT. From the study on the expansion of the 3D ex-vivo method using a suspension of micro-carrier in a bioreactor, obtain morphological and immunophenotyping results that are in accordance with human MSC characteristics. Likewise, it is proven that *Macaca fascicularis* amniotic membranes derived-MSC is multipotent; can differentiate into 3 main strains (osteocytes, chondrocytes and adipocytes).

In this present study, 3D AM-MSCs were superior to the gold standard therapy for burn wound (Burnazine) in improving burn wound injury healing in our NHP model, Implantation of 3D AM-MSCs significantly accelerated the wound closure rate; the wound closure rate were significantly accelerated in day 7, followed by an increase of the rates of HGF concentrations for increases migration, reflecting higher differentiation of many cells, especially epithelialization<sup>29</sup> and VEGF for angiogenesis that decreases in

time dependent manner along remodelling phase. These advancements, accompanied with the dry wound conditions, prevented excessive cicatrisation-scars and remodelling of hair growth while the body-weight of NHP treated with 3D AM-MSCs was restored more quickly and they also displayed much better mobility compared to the negative control group and gold standard group (Table 2).

Furthermore, HGFs play a role in the metabolism of collagen fibrils, which are stable under the physiological conditions of the extracellular environment.<sup>30</sup> Besides this direct modification of the collagen, HGF has been shown to influence transforming growth factor A1, which, in turn, modifies collagen-synthesis and –degradation.<sup>31</sup> During the wound healing process, the imbalance of collagen synthesis and degradation resulting in excess accumulation of dermal collagen can lead to the scar complications.<sup>32</sup> The production of collagen can be a double-edged sword: on the one hand, it is necessary for wound healing; on the other hand, excess deposition of collagen can result in scarring;<sup>33</sup> as in our study shown that collagen in negative control (NaCl 0,9%) 20x higher and the gold standard (Burnazine) 10x higher compared 3D AM-MSCs groups, which made scars formation. Therefore, the appropriate expression of collagen is required for ideal wound healing such as shown in our 3D AM-MSCs treatment. There were no significant different in burn wound closure rate and measurement of growth factors between both dose of  $5 \times 10^5$  and  $2 \times 10^6$  3D AM-MSCs. Therefore, we suggests to use a minimum therapeutical dose to reach optimal burn wound closure and healing.

## **Conclusion**

In conclusion, we demonstrate the potential treatment of 3D AM-MSCs for burn wound injuries in NHPs that effectively promoted rapid wound closure. Our results shows that

3D AM-MSCs potentially facilitate regenerative medicine in industrial scale productions and promote stem cell therapy in the future, especially burn wound injuries in clinical set-up.

## **Declarations**

### **Ethics Approval and Consent to Participate**

This study was approved by the Ethics Committee of the Institutional of Animal Care and Use Ethics Commission (IACUC) of PT Bio Farma (Persero) No. 01/IACUC-BF/III/2017 with a validity period of 2 years, April 14<sup>th</sup> , 2017–2019.

### **Consent to Publish**

N/A

### **Availability of data and materials section**

Authors declare that the data will not be shared, unless requested.

### **Competing Interests**

Authors have declared that no competing interests exist.

### **Funding**

R.N. supported by the Research and Development of PT Bio Farma (Persero), Life Sciences Company, Bandung, Indonesia, 2018/2019. A.F. supported by the Grants-in-Aid from the Ministry of Research, Technology and Higher Education of the Republic of Indonesia 06/E/KPT/2019 (World Class Research).

### **References**

1. Hermans MHE. A general overview of burn care. *Int Wound J.* 2005;2:206-220.
2. Dhande Priti P, Raj S, Kureshee Nargis I, Sanghavi Dhara R, Pandit Vijaya A. Burn wound healing potential of jatyadi formulations in rats. *Res J Pharm Biol Chem Sci.* 2012;3:747-754.
3. Singh V, Devgan L, Bhat S, Milner SM. The pathogenesis of burn wound conversion. *Ann Plast Surg.* 2007;59:109-115.

4. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. Topical antimicrobials for burn wound infections. *Recent Pat Antiinfect Drug Discov.* 2010;5:124-151.
5. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. *Clin Microbiol Rev.* 2006;19:403-434.
6. Kastrinaki MC, Andreakou I, Charbord P and Papadaki HA. Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. *Tissue Eng Part C Methods* 2008; 14: 333-339.
7. Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, Megges M, Prigione A, Adjaye J, Kassem M and Aldahmash A. Human Stromal (Mesenchymal) Stem Cells from Bone Marrow, Adipose Tissue and Skin Exhibit Differences in Molecular Phenotype and Differentiation Potential. *Stem Cell Rev* 2013; 1: 132-43.
8. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, LeRoux MA. Concise Review: Role of Mesenchymal Stem Cells in Wound Repair. *Stem Cells Transl Med.* 2012; 1(2): 142–149.
9. Islam MM, Md. Hossain ML, Diba F, Hasan MZ, Juliana FM, Asaduzzaman SM. The Combined Effect of Amniotic Membrane and Moringa oleifera Leaves Derived Gel for Wound and Burn Healing in Rat Model. *Regen. Eng. Transl. Med.* 2018; 4: 177.
10. Navas A, Magaña-Guerrero FS, Domínguez-López A, Chávez-García C, Partido G, Graue-Hernández EO, Sánchez-García FJ, Garfias Y. Anti-Inflammatory and Anti- Fibrotic Effects of Human Amniotic Membrane Mesenchymal Stem Cells and Their Potential in Corneal Repair. *Stem Cells Transl Med.* 2018; 7(12): 906–917.
11. De Rijk EPCT, Van Esch E. The Macaque Placenta - A Mini-Review. *Toxicol Pathol.* 2008; 36(7S):108S–118S.
12. Pogozhykh O, Pogozhykh D, Neehus A-L, Hoffmann A, Blasczyk R, Müller T. Molecular and cellular characteristics of human and non-human primate multipotent stromal cells from the amnion and bone marrow during long term culture. *Stem Cell Res Ther.* 2015;6(1):150.

13. Reinisch A, Strunk D. Isolation and animal serum free expansion of human umbilical cord derived mesenchymal stromal cells (MSCs) and endothelial colony forming progenitor cells (ECFCs). *J Vis Exp*. 2009;32:1525.
14. Wharton TW. 1996. *Adenographia*, Translated by S. Freer. Oxford, UK: Oxford University Press. pp. 242–8.
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, *et al.* 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8(4):315–7.
16. Kastrinaki MC, Andreakou I, Charbord P, Papadaki HA. 2008. Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. *Tissue Eng Part C Methods* 14(4):333–9.
17. Mrugala D, Dossat N, Ringe J, Delorme B, Coffy A, Bony C, *et al.* 2009. Gene expression profile of multipotent mesenchymal stromal cells: identification of pathways common to TGFb3/BMP2-induced chondrogenesis. *Cloning Stem Cells* 11(1):61–76.
18. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. Topical antimicrobials for burn wound infections. *Recent Pat Antiinfect Drug Discov*. 2010;5:124-151.
19. Papadimitropoulos A, Piccinini E, Brachat S, Braccini A, Wendt D, Barbero A, *et al.* Expansion of human mesenchymal stromal cells from fresh bone marrow in a 3D scaffold-based system under direct perfusion. *PLoS One*. 2014;9(7):1–12.
20. Li B, Wang X, Wang Y, Gou W, Yuan X, Peng J, *et al.* Past, present, and future of microcarrier-based tissue engineering. *J Orthop Transl [Internet]*. 2015;3(2):51–7.
21. Fairbank A. Enabling Cell Therapy Manufacturing. *Bioprocess Int*. 2015;13(8).
22. Yamaguchi Y, Ohno J, Sato A, Kido H, Fukushima T, Bruder S, *et al.* Mesenchymal stem cell spheroids exhibit enhanced in-vitro and in-vivo osteoregenerative potential. *BMC Biotechnol [Internet]*. 2014;14(1):105.
23. Rehman R. Regenerative Potential Of Placental Stem Cells For The Regenerative Potential Of Placental Stem Cells For The. 2013;1–162.
24. Lr M, Shareef S, Ev B. Stem Cells to Improve Burn Wound Healing. 2015;5:3–5.

25. Lee DE, Ayoub N, Agrawal DK. Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy. *Stem Cell Res Ther* [Internet]. 2016;7(1):37.
26. Fujiyama A, Watanabe H, Toyoda A, Taylor TD, Itoh T, Tsai SF, Park HS, Yaspo ML, Lehrach H, Chen Z, Fu G, Saitou N, Osoegawa K, de Jong PJ, Suto Y, Hattori M, Sakaki Y. 2002. Construction and analysis of a human-chimpanzee comparative clone map. *Science*, 295(5552): 131-134.
27. Lu YR, Wang LN, Jin X, Chen YN, Cong C, Yuan Y, Li YC, Tang WD, Li HX, Wu XT, Li YP, Wang L, Cheng JQ. 2008. A preliminary study on the feasibility of gene expression profile of rhesus monkey detected with human microarray. *Transplantation Proceedings*, 40(2): 598-602.
28. He S, Wang D, Wei L. 2013. Practical and critical instruction for nonhuman primate diabetic models. *Transplantation Proceedings*, 45(5): 1856-1865.
29. Conway K, Price P, Harding KG, Jiang WG (2006) The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. *Wound Repair and Regeneration* 14: 2-10.
30. Frost J, Ramsay M, Mia R, Moosa L, Musenge E, Tikly M. Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. *Rheumatology* 2012;51:1049-52.
31. Nalesnik MA, Michalopoulos GK. Growth factor pathways in development and progression of hepatocellular carcinoma. *Front Biosci* 2012;4:1487-517.
32. Sidgwick GP, Bayat A (2012) Extracellular matrix molecules implicated in hypertrophic and keloid scarring. *J Eur Acad Dermatol Venereol* 26: 141–152.
33. Verhaegen PD, Schouten HJ, Tigchelaar-Gutter W, van Marle J, van Noorden CJ, et al. (2012) Adaptation of the dermal collagen structure of human skin and scar tissue in response to stretch: An experimental study. *Wound Repair Regen* 20: 658–666.

## Figure Legends

- Figure 1. *Macaca fascicularis* distribution areas (red) as a native of Southeast Asia's animal, including Indonesia, Malaysia, Thailand and Indochina.
- Figure 2. Culture of 2D AM-MSCs. The first hours the cells were mostly round or oval in shape; after the third day most of the cells were adherent to the plate, exhibiting spindle-shape/fibroblast-like cell morphology with swirling in pattern, has reached confluence (inverted microscope, 100× magnification).
- Figure 3. AM-MSCs *Macaca fascicularis* in 3D micro-carrier Citodex-1 as empty (upper) and confluent (lower) (A), cells stained blue in DAPI (B) and stained red in propidium iodide (PI) (C).
- Figure 4. Flow cytometric histograms of 3D AM-MSCs *Macaca fascicularis*. The green line represents control and the solid purple line represent the specific positive markers (CD73, CD90 and CD105) indicated (A). The green line represents control and the solid purple line represent the specific negative-panel markers (CD34/45/11b/19/HLA-DR) and FITC-HLA-DR as indicated (B).
- Figure 5. Osteogenic differentiation was determined by the presence of calcium deposits characteristic of osteoblasts detected by alizarin red stain AM-MSCs were also tested for osteogenic differentiation (left). Chondrogenic differentiation was determined by the presence of chondrocytes detected using alcian blue stain (middle). Adipogenic differentiation was determined by the presence of adipocytes with lipid drops detected using Oil-red O (OR-O) stain (right).
- Figure 6. The development of the percentage of wound closure among negative control (NaCl 0,9%), gold standard (Burnazine) and 3D AM-MSCs treated groups on day 7, 14, 21 and 28 after wound induction.
- Figure 7. The representative pictures of wound closure progress of four groups in time dependent manner.
- Figure 8. Effects of 3D AM-MSCs activated growth factors, such as on HGF level on daily basis from day 7 to 28 (A); on the mean value of HGF and VEGF (B).
- Figure 9. Effects of 3D AM-MSCs activated growth factors, such as on VEGF level on daily basis from day 7 to 28.
- Figure 10. Effects of 3D AM-MSCs activated growth factors, such as on collagen level on daily basis from day 7 to 28 (A) and on the mean value of collagen (B).

## TABLES

Table 1. The PDT 2D AM-MSCs vs. 3D AM-MSCs isolated *Macaca fascicularis* cells

Culture Methods	Population Doubling Time (PDT) in days						p-value
	P1-0	P1-1	P1-2	P2-0	P2-1	P2-2	
2D	4,0	3,4	4,2	3,6	4,0	3,8	0,000*
3D	2,7	1,2	1,1	1,2	1,1	1,15	

Note: \*Significant


Table 2. Weight of *Macaca fascicularis* measured after each treatments from day 7 up to 28

Treatment	<i>Macaca fascicularis</i> body weight (gram) in time dependent manner			
	Day 7	Day 14	Day 21	Day 28
NaCl 0,9%	2870	2590	2560	2450
Burnazine	2830	2780	2680	2680
5x10 <sup>5</sup> MSCs	2880	2900	2920	3050
2x10 <sup>6</sup> MSCs	2860	2880	2910	3090


Fig 1. 3D AM-MSCs NHP\_mapR0.jpg  
[Click here to download high resolution image](#)




**Fig 2. 3D AM-MSCs NHP\_2DR0.jpg**  
[Click here to download high resolution image](#)



**Fig 3. 3D AM-MSCs NHP\_3DR0.jpg**  
[Click here to download high resolution image](#)





Histogram Statistics


\* Numerator Histogram \*

File: MIX 3.017      Log Data Units: Linear Values  
 Sample ID: MIX 3      Patient ID:

\* Denominator Histogram \*

File: ISOTYPE 3.016      Log Data Units: Linear Values  
 Sample ID: ISOTYPE 3      Patient ID:

Marker	Events	% Gated	% Total
All	10000	100.00	100.00
M1	9897	98.97	98.97



Histogram Statistics


\* Numerator Histogram \*

File: MIX 3.017      Log Data Units: Linear Values  
 Sample ID: MIX 3      Patient ID:

\* Denominator Histogram \*

File: ISOTYPE 3.016      Log Data Units: Linear Values  
 Sample ID: ISOTYPE 3      Patient ID:

Marker	Events	% Gated	% Total
All	8670	99.38	86.70
M1	8445	96.80	84.45



Histogram Statistics

\* Numerator Histogram \*


File: MIX2.009      Log Data Units: Linear Values  
 Sample ID: MIX2      Patient ID:

\* Denominator Histogram \*

File: ISOTYPE 2.004      Log Data Units: Linear Values  
 Sample ID: ISOTYPE 2      Patient ID:

Marker	Events	% Gated	% Total
All	7539	97.15	75.39
M1	6084	78.40	60.84

# CD34/CD45/CD11b/CD19/HLA-DR



## Histogram Statistics


File: MIX 1.007

Log Data Units: Linear Values

Sample ID: MIX 1

Patient ID:

Marker	Events	% Gated	% Total
All	8305	100.00	83.05
M1	40	0.48	0.40



**Fig 5. 3D AM-MSCs NHP\_diffR0.jpg**  
[Click here to download high resolution image](#)





Fig 6. 3D AM-MSCs NHP\_wound closeR0.jpg  
[Click here to download high resolution image](#)



	(Days) 7	14	21	28
NaCl 0,9%	12.5 ± 2.7	20.0 ± 0.0	20.9 ± 2.0	20.1 ± 2.1
Burnazine	20.5 ± 0.0	25.0 ± 0.0	35.0 ± 0.0	60.0 ± 7.1
5x10 <sup>5</sup> MSCs	30.0 ± 0.0	35.0 ± 0.0	57.0 ± 2.4	92.1 ± 2.7
2x10 <sup>6</sup> MSCs	30.0 ± 4.5	35.0 ± 0.0	60.0 ± 4.1	91.2 ± 2.4

Fig 7. 3D AM-MSCs NHP\_WC picR0.jpg  
[Click here to download high resolution image](#)





Fig 8A. 3D AM-MSCs NHP\_dHEGFR0.jpg  
[Click here to download high resolution image](#)

## HGF Concentration in Serum






Fig 9. 3D AM-MSCs NHP\_dVEGFR0.jpg  
[Click here to download high resolution image](#)

## VEGF Concentration in Serum





Fig 10A. 3D AM-MSCs NHP\_dCoIR0.jpg  
[Click here to download high resolution image](#)



## Mean of Collagen Concentration

